Empagliflozin and Metformin
Brand name: Synjardy
Empagliflozin and Metformin comes in 14 pill versions in our database, in 10 strengths, from 2 manufacturers. Check the imprint to tell them apart.
Empagliflozin and Metformin pill images
5 mg / 500 mg 1 pill
5 mg / 850 mg 1 pill
5 mg / 1000 mg 2 pills
- S5 1000 Empagliflozin, Metformin Hydrochloride 5 mg / 1000 mg Green, oval, 19 mm Used for type 2 diabetes
- S5 1000 Empagliflozin and Metformin Hydrochloride 5 mg / 1000 mg Brown, oval, 21 mm Used for type 2 diabetes
10 mg / 1000 mg 1 pill
12.5 mg / 500 mg 2 pills
- S12 500 Empagliflozin and Metformin Hydrochloride 12.5 mg / 500 mg Purple, oval, 16 mm Used for type 2 diabetes
- No picture yet DIN 02456605 Empagliflozin and Metformin Hydrochloride 12.5 mg / 500 mg Synjardy, Tablet, sold in Canada Used for type 2 diabetes
12.5 mg / 1000 mg 3 pills
- S12 1000 Empagliflozin, Metformin Hydrochloride 12.5 mg / 1000 mg Blue, oval, 19 mm Used for type 2 diabetes
- S12 1000 Empagliflozin and Metformin Hydrochloride 12.5 mg / 1000 mg Purple, oval, 21 mm Used for type 2 diabetes
- No picture yet DIN 02456621 Empagliflozin and Metformin Hydrochloride 12.5 mg / 1000 mg Synjardy, Tablet, sold in Canada Used for type 2 diabetes
25 mg / 1000 mg 1 pill
500 mg / 5 mg 1 pill
850 mg / 12.5 mg 1 pill
1000 mg / 5 mg 1 pill
What is Empagliflozin and Metformin used for?
Empagliflozin and Metformin is used for type 2 diabetes.
- Medicine type
- Diabetes medicine (SGLT2 inhibitor); diabetes medicine (biguanide)
Official uses from the US prescribing label
SYNJARDY
SYNJARDY is a combination of empagliflozin and metformin hydrochloride (HCl) immediate-release indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients aged 10 years and older with type 2 diabetes mellitus.
SYNJARDY XR
SYNJARDY XR is a combination of empagliflozin and metformin HCl extended-release indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
Empagliflozin
Empagliflozin, when used as a component of SYNJARDY or SYNJARDY XR, is indicated in adults with type 2 diabetes mellitus to reduce the risk of:
- Cardiovascular (CV) death in adults with established CV disease.
- CV death and hospitalization for heart failure in adults with heart failure.
- Sustained decline in eGFR, end-stage kidney disease, CV death, and hospitalization in adults with chronic kidney disease at risk of progression.
Limitations of Use
- SYNJARDY and SYNJARDY XR are not recommended for use to improve glycemic control in patients with type 1 diabetes mellitus. It may increase the risk of diabetic ketoacidosis in these patients.
- Because of the metformin HCl component, the use of SYNJARDY or SYNJARDY XR is limited to patients with type 2 diabetes mellitus for all indications.
- Empagliflozin, when used as a component of SYNJARDY or SYNJARDY XR, is not recommended for the treatment of chronic kidney disease in patients with polycystic kidney disease or patients requiring or with a recent history of intravenous immunosuppressive therapy or greater than 45 mg of prednisone or equivalent for kidney disease. Empagliflozin is not expected to be effective in these populations.
From the FDA-approved label on DailyMed (published Aug 27, 2026).
Doctors sometimes prescribe a medicine for other reasons too. If you are not sure what yours is for, ask your pharmacist.